Huichuang Medical

Huichuang Medical

Providing innovative, professional solutions and services for neuroscience R&D. Learn more

Launch date
Market cap
-
Enterprise valuation
$55—83m (Dealroom.co estimates May 2024.)
Beijing China (HQ)
  • Edit
DateInvestorsAmountRound
N/A

N/A

Seed

CNY20.0m

Series A
*

CNY100m

Series A
*

CNY100m

Series B
*

CNY100m

Series B
Total Funding$44.0m

Recent News about Huichuang Medical

Edit
More about Huichuang Medicalinfo icon
Edit

HCmedx specializes in leveraging functional near infrared spectroscopy (fNIRS) technology to enhance adaptive decision-making and emotion regulation across various applications. The company focuses on providing advanced monitoring and evaluation tools that utilize fNIRS to assess brain activity and cortical activation. Their solutions are particularly impactful in environments such as air traffic control and rehabilitation, where precise and adaptive decision-making is critical. HCmedx serves a diverse range of clients, including healthcare providers, rehabilitation centers, and research institutions. Operating in the medical technology and neuroscience markets, the company employs a business model centered around the development and sale of specialized fNIRS-based products and services. Revenue is generated through product sales, service contracts, and research collaborations.

Keywords: fNIRS, adaptive decision-making, emotion regulation, brain activity, cortical activation, air traffic control, rehabilitation, neuroscience, medical technology, monitoring tools.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.